Alevin Therapeutics Ltd

Founded in 2022 as a spin-out from the Faculty of Science, Alevin Therapeutics is a biotechnology company focused on developing breakthrough medicines for patients with life-threatening diseases. The company targets areas of high unmet clinical need, including fibrosis – particularly idiopathic pulmonary fibrosis (IPF) – as well as liver and kidney disease and cancer. 

Alevin Therapeutics has developed a proprietary platform of novel small molecules that selectively target key pathways within complex integrin biology. By advancing its discovery- and preclinical-stage assets toward clinical application, the company aims to deliver safe and effective new therapies and to provide meaningful relief for millions of patients affected by severe, life-limiting conditions for which effective treatments are currently lacking.